Home/Filings/4/0001193125-26-009068
4//SEC Filing

Portnoy Mark L. 4

Accession 0001193125-26-009068

CIK 0000862692other

Filed

Jan 8, 7:00 PM ET

Accepted

Jan 9, 5:00 PM ET

Size

19.5 KB

Accession

0001193125-26-009068

Insider Transaction Report

Form 4
Period: 2026-01-07
Portnoy Mark L.
DirectorCo-CEO10% Owner
Transactions
  • Award

    Stock Option

    2026-01-07$3.89/sh+50,000$194,50050,000 total
    Exercise: $3.89From: 2026-01-07Exp: 2031-01-07Common Stock (50,000 underlying)
  • Award

    Stock Option

    2026-01-07$3.89/sh+25,000$97,25025,000 total
    Exercise: $3.89From: 2026-01-07Exp: 2031-01-07Common Stock (25,000 underlying)
Holdings
  • Common Stock

    821,973
  • Common Stock

    (indirect: By 401(k))
    42,266
  • Common Stock

    (indirect: By Partnership)
    71,529
  • Stock Option

    Exercise: $7.53From: 2019-08-30Exp: 2029-08-30Common stock (22,222 underlying)
    22,222
  • Stock Option

    Exercise: $7.28From: 2019-12-20Exp: 2029-12-20Common Stock (20,000 underlying)
    20,000
  • Stock Option

    Exercise: $12.27From: 2021-12-22Exp: 2028-12-22Common Stock (100,000 underlying)
    100,000
  • Stock Option

    Exercise: $4.77From: 2023-01-03Exp: 2028-01-03Common Stock (25,000 underlying)
    25,000
  • Stock Option

    Exercise: $4.30From: 2022-12-23Exp: 2027-12-23Common Stock (25,000 underlying)
    25,000
  • Stock Option

    Exercise: $6.47From: 2023-12-22Exp: 2028-12-22Common Stock (25,000 underlying)
    25,000
  • Stock Option

    Exercise: $8.08From: 2025-01-21Exp: 2030-01-21Common Stock (25,000 underlying)
    25,000
Footnotes (7)
  • [F1]Shares of common stock held by Capital Asset Fund #1 Limited Partnership, as to which Mark Portnoy may be deemed beneficial owner as its general partner.
  • [F2]Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term.
  • [F3]8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026.
  • [F4]Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.
  • [F5]Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027.
  • [F6]The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.
  • [F7]Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.

Documents

1 file

Issuer

CRYO CELL INTERNATIONAL INC

CIK 0000862692

Entity typeother

Related Parties

1
  • filerCIK 0001529249

Filing Metadata

Form type
4
Filed
Jan 8, 7:00 PM ET
Accepted
Jan 9, 5:00 PM ET
Size
19.5 KB